Elin Trampe takes over as CEO of Dicot AB

Press release: Uppsala, April 1, 2022. Elin Trampe is the new CEO of the pharmaceutical company Dicot starting today. Elin brings important experiences from e.g. business development, international partnerships and operational excellence. Elin's focus as new CEO will be to focus on taking the company into the next phase. Elin Trampe succeeds Göran Beijer, who remains in the company as a consultant.

Elin Trampe was hired by the company as COO and Deputy CEO in September 2021 and today succeeds Göran Beijer as CEO. Elin Trampe's main task as CEO will be to take the company into the next phase in the best way, where the focus will be on clinical studies, business development and partnerships with international pharmaceutical companies.

Dicot is developing the drug candidate LIB-01, which is expected to become a modern drug to better treat erectile dysfunction. The development is planned to take place in-house until phase 2 studies. Thereafter, Dicot's intention is to enter into collaboration agreements with established pharmaceutical companies to introduce LIB-01 on the world market.

"It's fantastic to lead a company that develops a new drug with potential to increase quality of life for so many people. This concerns more than half of all the world's men over 40 and their partners, and the need for new treatments is evident" says Elin Trampe, new CEO of Dicot.

Watch a filmed comment from Elin here.

"Elin has a very broad and valuable competence that is important to Dicot. With her strong drive and commitment, we will jointly with the rest of the management and the board, further develop the company as we now enter the next phase in the development of the company. ", says Eva Sjökvist Saers, Chairman of the Board of Dicot AB.

Elin Trampe has held several managerial and international roles in various companies and industries, including the global companies Mondelz International and GE Global Operations, as well as the pharmaceutical company Oasmia Pharmaceutical, where Elin had the role as CTO before joining Dicot. Elin Trampe has extensive experience in business development, strategic international partnerships, operational excellence and product development.

Göran Beijer will continue to be active in the company as a consultant with a focus on international partnerships and investor relations.

For further information, please contact:

Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: [email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 2,700 shareholders. For more information, please visit www.dicot.se.

Om Dicot Pharma

Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.



Kurs ()
Förändring ()
Marknad Spotlight Stock Market Kortnamn DICOT ISIN-kod SE0011178458


Elin Trampe Vd